Charles River acquires analytical CRO

By Melissa Fassbender contact

- Last updated on GMT

The acquisition is the latest in a series. (Image: iStock)
The acquisition is the latest in a series. (Image: iStock)

Related tags: Charles river, Executive officer, Management occupations, Chief executive officer

Charles River Laboratories has acquired Blue Stream Laboratories, expanding the company’s biologic and biosimilar development capabilities.

The Woburn, Massachusetts-based contract research organization (CRO) has expertise in structural and functional protein characterization programs as well as background in the development and validation of assays for current good manufacturing practice (cGMP) lot release and stability programs.

Through the acquisition, Charles River will have the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization.

James C. Foster, Chairman, President and Chief Executive Officer, said that the company is continuing to invest in expanding its biologics portfolio, especially as more biologic and biosimilar drugs are in development.

The investment announced today is the latest in a series of acquisitions, coming months after it finalized its acquisition of the CDMO, WIL Research.

As previously reported​, Charles River predicted 2016 to be a “robust year,” driven mainly by customer demand and enhanced strategic partnerships. 

Related news

Show more

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 07-Dec-2021 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

Related suppliers

Follow us


View more